182 related articles for article (PubMed ID: 15253689)
1. Considerations for assessing the cost of biologic agents in the treatment of psoriasis.
Rich SJ
J Manag Care Pharm; 2004 Jun; 10(3 Suppl B):S38-41. PubMed ID: 15253689
[TBL] [Abstract][Full Text] [Related]
2. A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis.
Fonia A; Jackson K; Lereun C; Grant DM; Barker JN; Smith CH
Br J Dermatol; 2010 Oct; 163(4):807-16. PubMed ID: 20662837
[TBL] [Abstract][Full Text] [Related]
3. Biological therapies for the treatment of severe psoriasis in patients with previous exposure to biological therapy: a cost-effectiveness analysis.
Sawyer LM; Wonderling D; Jackson K; Murphy R; Samarasekera EJ; Smith CH
Pharmacoeconomics; 2015 Feb; 33(2):163-77. PubMed ID: 25526841
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data.
Rustin MH
Br J Dermatol; 2012 Nov; 167 Suppl 3():3-11. PubMed ID: 23082810
[TBL] [Abstract][Full Text] [Related]
5. Redefining clinical response in psoriasis: targeting the pathological basis of disease.
Ortonne JP
J Drugs Dermatol; 2004; 3(1):13-20. PubMed ID: 14964742
[TBL] [Abstract][Full Text] [Related]
6. Alefacept treatment for chronic plaque psoriasis.
Dunn LK; Feldman SR
Skin Therapy Lett; 2010 Apr; 15(4):1-3. PubMed ID: 20361167
[TBL] [Abstract][Full Text] [Related]
7. Injectable biologic case studies.
Lipsy RJ
J Manag Care Pharm; 2004 May; 10(3 Suppl):S10-6; quiz S20. PubMed ID: 15228371
[TBL] [Abstract][Full Text] [Related]
8. Alefacept: a novel and selective biologic agent for the treatment of chronic plaque psoriasis.
Ortonne JP; Prinz JC
Eur J Dermatol; 2004; 14(1):41-5. PubMed ID: 14965795
[TBL] [Abstract][Full Text] [Related]
9. Paradoxical effects of cost reduction measures in managed care systems for treatment of severe psoriasis.
Yentzer BA; Yelverton CB; Simpson GL; Simpson JF; Hwang W; Balkrishnan R; Feldman SR
Dermatol Online J; 2009 Apr; 15(4):1. PubMed ID: 19450394
[TBL] [Abstract][Full Text] [Related]
10. Anti-TNF agents for the treatment of psoriasis.
Kircik LH; Del Rosso JQ
J Drugs Dermatol; 2009 Jun; 8(6):546-59. PubMed ID: 19537380
[TBL] [Abstract][Full Text] [Related]
11. Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis.
Liu Y; Wu EQ; Bensimon AG; Fan CP; Bao Y; Ganguli A; Yang M; Cifaldi M; Mulani P
Adv Ther; 2012 Jul; 29(7):620-34. PubMed ID: 22843208
[TBL] [Abstract][Full Text] [Related]
12. Prior authorization for topical psoriasis treatments: is it cost-beneficial for managed care?
Balkrishnan R; Bhosle MJ; Fleischer AB; Feldman SR
J Dermatolog Treat; 2010 May; 21(3):178-84. PubMed ID: 19821787
[TBL] [Abstract][Full Text] [Related]
13. The status of biologic therapies in the treatment of moderate to severe psoriasis.
Menter A
Cutis; 2009 Oct; 84(4 Suppl):14-24. PubMed ID: 19916298
[TBL] [Abstract][Full Text] [Related]
14. A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency.
Staidle JP; Dabade TS; Feldman SR
Expert Opin Pharmacother; 2011 Sep; 12(13):2041-54. PubMed ID: 21736530
[TBL] [Abstract][Full Text] [Related]
15. New treatments for psoriasis: which biologic is best?
Nelson AA; Pearce DJ; Fleischer AB; Balkrishnan R; Feldman SR
J Dermatolog Treat; 2006; 17(2):96-107. PubMed ID: 16766334
[TBL] [Abstract][Full Text] [Related]
16. Clinical update on alefacept: consideration for use in patients with psoriasis.
Gade JN
J Manag Care Pharm; 2004 Jun; 10(3 Suppl B):S33-7. PubMed ID: 15253688
[TBL] [Abstract][Full Text] [Related]
17. Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan.
Feldman SR; Evans C; Russell MW
J Dermatolog Treat; 2005 Feb; 16(1):37-42. PubMed ID: 15897166
[TBL] [Abstract][Full Text] [Related]
18. Clobetasol propionate spray 0.05% add-on therapy to a stable regimen of biologic treatment in patients with moderate to very severe plaque psoriasis.
Feldman SR; Koo JY; Johnson LA; Preston NJ
Cutis; 2009 Oct; 84(4 Suppl):25-32. PubMed ID: 19916299
[TBL] [Abstract][Full Text] [Related]
19. The cost effectiveness of biologic therapy for the treatment of chronic plaque psoriasis in real practice settings in Italy.
Spandonaro F; Ayala F; Berardesca E; Chimenti S; Girolomoni G; Martini P; Peserico A; Polistena B; Puglisi Guerra A; Vena GA; Altomare G; Calzavara Pinton P
BioDrugs; 2014 Jun; 28(3):285-95. PubMed ID: 24567261
[TBL] [Abstract][Full Text] [Related]
20. Managed care's perspective on treatment of plaque psoriasis.
Sullivan TJ
Manag Care; 2003 May; 12(5 Suppl):14-7; discussion 20-1. PubMed ID: 18564554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
